Display options
Cite
Fallahi P, Ferrari SM, Mazzi V, et al. Personalization of targeted therapy in advanced thyroid cancer. Curr Genomics. 2014;15(3):190-202doi: 10.2174/1389202915999140404101902.
Fallahi, P., Ferrari, S. M., Mazzi, V., Vita, R., Benvenga, S., & Antonelli, A. (2014). Personalization of targeted therapy in advanced thyroid cancer. Current genomics, 15(3), 190-202. https://doi.org/10.2174/1389202915999140404101902
Fallahi, Poupak, et al. "Personalization of targeted therapy in advanced thyroid cancer." Current genomics vol. 15,3 (2014): 190-202. doi: https://doi.org/10.2174/1389202915999140404101902
Fallahi P, Ferrari SM, Mazzi V, Vita R, Benvenga S, Antonelli A. Personalization of targeted therapy in advanced thyroid cancer. Curr Genomics. 2014 Jun;15(3):190-202. doi: 10.2174/1389202915999140404101902. PMID: 24955027; PMCID: PMC4064559.
Copy Download .nbib Format: NLM
Share it on

Curr Genomics. 2014 Jun;15(3):190-202. doi: 10.2174/1389202915999140404101902.

Personalization of targeted therapy in advanced thyroid cancer.

Current genomics

Poupak Fallahi, Silvia Martina Ferrari, Valeria Mazzi, Roberto Vita, Salvatore Benvenga, Alessandro Antonelli

Affiliations

  1. Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  2. Department of Clinical & Experimental Medicine, Section of Endocrinology, University of Messina, Messina, Italy.

PMID: 24955027 PMCID: PMC4064559 DOI: 10.2174/1389202915999140404101902

Abstract

Although generally the prognosis of differentiated thyroid carcinoma (DTC) is good, approximately 5% of people are likely to develop metastases which fail to respond to radioactive iodine, and other traditional therapies, exhibiting a more aggressive behavior. Nowadays, therapy is chosen and implemented on a watch-and-wait basis for most DTC patients. Which regimen is likely to work best is decided on the basis of an individual's clinical information, but only data referring to outcomes of groups of patients are employed. To predict the best course of therapy, an individual patient's biologic data is rarely employed in a systematic way. Anyway, the use of not expensive individual genomic analysis could lead us to a new era of patient-specific and personalized care. Recently, key targets that are now being evaluated in the clinical setting have been evidenced in the pathogenesis of these diseases. Some of the known genetic alterations playing a crucial role in the development of thyroid cancer include B-Raf gene mutations, rearranged during transfection/ papillary thyroid carcinoma gene rearrangements, and vascular endothelial growth factor receptor-2 angiogenesis pathways. The development of targeted novel compounds able to induce clinical responses and stabilization of disease has overcome the lack of effective therapies for DTC, which are resistant to radioiodine and thyroid stimulating hormone-suppressive therapy. Interestingly, the best responses have been demonstrated in patients treated with anti-angiogenic inhibitors such as vandetanib and XL184 in medullary thyroid cancer, and sorafenib in papillary and follicular DTC.

Keywords: Personalized therapy; Sorafenib; Targeted therapy; Thyroid cancer; Vandetanib; XL184.

References

  1. Eur J Endocrinol. 2009 Dec;161(6):923-31 - PubMed
  2. CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 - PubMed
  3. Ann Intern Med. 1991 Jul 15;115(2):133-47 - PubMed
  4. Cancer. 1997 Feb 1;79(3):564-73 - PubMed
  5. Biomed Pharmacother. 2008 Oct;62(8):559-63 - PubMed
  6. N Engl J Med. 2009 Sep 3;361(10):947-57 - PubMed
  7. Thyroid. 2008 Mar;18(3):317-23 - PubMed
  8. Int J Oncol. 2004 Jan;24(1):89-95 - PubMed
  9. Clin Cancer Res. 2005 Nov 1;11(21):7664-73 - PubMed
  10. J Clin Endocrinol Metab. 2003 Apr;88(4):1897-902 - PubMed
  11. Endocr Relat Cancer. 2006 Dec;13(4):1173-83 - PubMed
  12. Endocrine. 2007 Apr;31(2):105-13 - PubMed
  13. Mol Cancer Ther. 2004 Aug;3(8):1011-20 - PubMed
  14. J Clin Oncol. 2010 Feb 20;28(6):1061-8 - PubMed
  15. Horm Metab Res. 2008 May;40(5):323-8 - PubMed
  16. J Clin Oncol. 2010 Feb 10;28(5):767-72 - PubMed
  17. Science. 2004 Jul 16;305(5682):399-401 - PubMed
  18. Surgery. 2002 Dec;132(6):960-6; discussion 966-7 - PubMed
  19. Eur J Cancer. 2003 Sep;39(14):2006-11 - PubMed
  20. Biochem Pharmacol. 2011 Jun 1;81(11):1309-16 - PubMed
  21. Int J Exp Pathol. 2009 Jun;90(3):284-94 - PubMed
  22. Endocr Relat Cancer. 2005 Jun;12(2):291-303 - PubMed
  23. Clin Cancer Res. 2010 Nov 1;16(21):5260-8 - PubMed
  24. J Endocrinol Invest. 2007 Nov;30(10):RC31-4 - PubMed
  25. Thyroid. 1995 Feb;5(1):25-8 - PubMed
  26. Cancer Treat Res. 2004;122:237-64 - PubMed
  27. J Clin Oncol. 2012 Jan 10;30(2):134-41 - PubMed
  28. Expert Rev Mol Diagn. 2008 Jan;8(1):83-95 - PubMed
  29. Oncogene. 1995 Nov 2;11(9):1737-43 - PubMed
  30. Int J Radiat Oncol Biol Phys. 2004;59(2 Suppl):21-6 - PubMed
  31. Cancer Res. 2002 Jun 15;62(12):3408-16 - PubMed
  32. Clin Cancer Res. 2013 Aug 1;19(15):4239-48 - PubMed
  33. Eur J Endocrinol. 2008 Sep;159(3):283-91 - PubMed
  34. Clin Cancer Res. 2009 Jan 15;15(2):485-91 - PubMed
  35. J Clin Oncol. 2011 Jul 1;29(19):2660-6 - PubMed
  36. World J Surg. 1996 Sep;20(7):867-71 - PubMed
  37. Cancer Res. 2008 Jun 1;68(11):4183-91 - PubMed
  38. Eur J Endocrinol. 2007 Aug;157(2):215-20 - PubMed
  39. J Clin Endocrinol Metab. 2006 Jan;91(1):213-20 - PubMed
  40. J Clin Endocrinol Metab. 2013 Jun;98(6):2392-400 - PubMed
  41. Endocr Rev. 2006 Aug;27(5):535-60 - PubMed
  42. J Clin Endocrinol Metab. 2007 Sep;92(9):3466-9 - PubMed
  43. Jpn J Cancer Res. 2002 Dec;93(12):1358-65 - PubMed
  44. Clin Endocrinol (Oxf). 2013 May;78(5):760-7 - PubMed
  45. Laryngoscope. 2008 Aug;118(8):1372-6 - PubMed
  46. Eur J Endocrinol. 2011 Aug;165(2):315-22 - PubMed
  47. J Med Genet. 2000 Nov;37(11):817-27 - PubMed
  48. Eur J Endocrinol. 2012 Nov;167(5):643-50 - PubMed
  49. Biomark Insights. 2008 Apr 29;3:237-252 - PubMed
  50. J Clin Oncol. 2005 Aug 20;23(24):5474-83 - PubMed
  51. Clin Endocrinol (Oxf). 2008 Jul;69(1):148-52 - PubMed
  52. J Clin Endocrinol Metab. 2014 Apr;99(4):E572-81 - PubMed
  53. Lancet Oncol. 2004 Jul;5(7):419-29 - PubMed
  54. Cancer Res. 2009 Feb 15;69(4):1536-44 - PubMed
  55. J Clin Endocrinol Metab. 2002 Aug;87(8):3947-52 - PubMed
  56. J Clin Oncol. 2002 Sep 1;20(17):3568-9 - PubMed
  57. Clin Cancer Res. 2006 Mar 15;12(6):1785-93 - PubMed
  58. Lancet Oncol. 2012 Sep;13(9):897-905 - PubMed
  59. Clin Endocrinol (Oxf). 2009 Jun;70(6):946-53 - PubMed
  60. J Clin Oncol. 2008 Oct 10;26(29):4708-13 - PubMed
  61. J Clin Endocrinol Metab. 2010 Jun;95(6):2588-95 - PubMed
  62. J Clin Oncol. 2009 Apr 1;27(10):1675-84 - PubMed
  63. BioDrugs. 2013 Dec;27(6):615-28 - PubMed
  64. Cancer Res. 2002 Feb 15;62(4):1077-82 - PubMed
  65. J Biol Chem. 1996 Jan 12;271(2):695-701 - PubMed
  66. Br J Cancer. 2001 May 18;84(10):1289-90 - PubMed
  67. J Clin Endocrinol Metab. 2005 Dec;90(12):6373-9 - PubMed
  68. J Endocrinol. 1999 Apr;161(1):41-9 - PubMed
  69. J Clin Endocrinol Metab. 2012 Apr;97(4):E528-36 - PubMed
  70. J Clin Endocrinol Metab. 2010 Jun;95(6):2664-71 - PubMed
  71. N Engl J Med. 2005 Jul 14;353(2):172-87 - PubMed
  72. Thyroid. 2013 May;23(5):600-4 - PubMed
  73. Endocr Relat Cancer. 2005 Jun;12(2):245-62 - PubMed
  74. IDrugs. 2010 Feb;13(2):112-21 - PubMed
  75. J Clin Endocrinol Metab. 2011 Feb;96(2):E288-96 - PubMed
  76. Endocr Rev. 2004 Aug;25(4):581-611 - PubMed
  77. Acta Cytol. 2002 May-Jun;46(3):591-5 - PubMed
  78. Am J Pathol. 1999 Dec;155(6):1967-76 - PubMed
  79. J Pediatr Surg. 2004 Oct;39(10):1500-5 - PubMed
  80. Clin Cancer Res. 2008 May 15;14(10):2895-9 - PubMed
  81. Anticancer Res. 2003 Sep-Oct;23(5A):3601-6 - PubMed
  82. Endocrinology. 2006 Sep;147(9):4463-75 - PubMed
  83. Clin Cancer Res. 2012 Jul 15;18(14):3722-30 - PubMed
  84. Hum Pathol. 2009 Nov;40(11):1517-27 - PubMed
  85. N Engl J Med. 2003 Mar 13;348(11):994-1004 - PubMed
  86. Oncogene. 1999 Aug 26;18(34):4860-9 - PubMed
  87. Eur J Cancer. 1990;26(7):834-8 - PubMed
  88. Surgery. 2001 May;129(5):552-8 - PubMed
  89. Nat Clin Pract Oncol. 2006 Oct;3(10):564-74 - PubMed
  90. Cancer Chemother Pharmacol. 2007 Mar;59(4):467-75 - PubMed
  91. BMC Cancer. 2011 Jul 22;11:309 - PubMed
  92. Surg Today. 2007;37(1):34-7 - PubMed
  93. Nat Med. 1996 May;2(5):561-6 - PubMed
  94. J Clin Endocrinol Metab. 2003 May;88(5):2318-26 - PubMed
  95. N Engl J Med. 2008 Jul 3;359(1):31-42 - PubMed
  96. Thyroid. 2003 May;13(5):479-84 - PubMed
  97. J Clin Endocrinol Metab. 2010 Nov;95(11):5018-27 - PubMed
  98. Lancet Oncol. 2010 Oct;11(10):962-72 - PubMed
  99. J Clin Endocrinol Metab. 2006 Oct;91(10):4070-6 - PubMed
  100. Blood. 2007 Oct 1;110(7):2242-9 - PubMed
  101. J Clin Oncol. 2008 Oct 10;26(29):4714-9 - PubMed
  102. BMC Cancer. 2011 Aug 11;11:349 - PubMed
  103. J Biol Chem. 2001 Sep 21;276(38):35808-17 - PubMed
  104. Nucl Med Commun. 2004 Dec;25(12):1183-6 - PubMed
  105. Thyroid. 2013 Dec;23(12):1569-77 - PubMed
  106. Curr Genomics. 2011 Dec;12(8):626-31 - PubMed
  107. J Clin Endocrinol Metab. 2006 Feb;91(2):614-20 - PubMed
  108. N Engl J Med. 2001 Apr 5;344(14):1031-7 - PubMed
  109. Oncogene. 1996 Apr 18;12(8):1821-6 - PubMed
  110. Thyroid. 2011 Nov;21(11):1171-4 - PubMed
  111. J Clin Endocrinol Metab. 2001 May;86(5):2170-7 - PubMed
  112. N Engl J Med. 2002 Aug 15;347(7):472-80 - PubMed
  113. N Engl J Med. 2006 Jun 15;354(24):2542-51 - PubMed
  114. Thyroid. 2005 Mar;15(3):222-31 - PubMed
  115. J Clin Oncol. 2009 Aug 10;27(23):3794-801 - PubMed
  116. Am J Surg Pathol. 2005 Apr;29(4):544-9 - PubMed
  117. N Engl J Med. 2011 Jan 27;364(4):340-50 - PubMed

Publication Types